background: gonadotrophin-releasing hormone (gnrh) agonist is used for controlling ovarian stimulation in assisted reproductive technology (art) cycles which has some benefits. objective: to compare the efficacy of two different formulations of gnrh agonist: short-acting and long-acting, for art protocols. materials and methods: in a prospective randomized study, one hundred women who underwent...

The goal of ovarian Stimulation for assisted reproductive technologies (ART) is obtaining multifollicular growth ovarian hyper stimulation syndrome (OHSS) is one of the most Severe and also potentially Life-threatening complications, which happens in 1-10% of IVF cycles. The most common risk factors which are related to OHSS are polycystic ovarian syndrome (PCOS), younger age, high preovulatory...

This article is a systematic review of the literature on utilization of gonadotrophin-releasing hormone antagonists (GnRH-ant) for ovarian stimulation for IVF in special patient groups. Summarized by meta-analysis are the data from randomized controlled trials (RCT) in which GnRH-agonist (GnRH-a) and GnRH-ant were compared (eight RCT for poor response, four RCT for PCOS). Also reviewed are the ...

The response in cattle to treatment with gonadotrophin releasing hormone (GnRH) agonist includes downregulation of GnRH receptors on gonadotrophe cells, desensitisation of the anterior pituitary gland to endogenous GnRH, and the abolition of pulsatile release of LH. In bulls, a tonic pattern of LH release is associated with increased secretion of testosterone, which persists for the duration of...

Epithelial ovarian cancer, which accounts for 80-90% of all ovarian cancers, is the most common cause of death from gynecological malignancies and is believed to originate from the ovarian surface epithelium. In the present study we investigated the expression of GnRH and its receptor in human ovarian surface epithelial (hOSE) cells and provided novel evidence that GnRH may have antiproliferati...

Background Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication, which can cause high morbidity and mortality. Use of gonadotropin releasing hormone (GnRH) agonist instead of human chorionic gonadotropin (hCG) in GnRH antagonist cycles causes luteinizing hormone surge by GnRH stimulation which reduces the risk of OHSS by reducing the total amount of gonadotropin; however, ther...

Background GnRH agonist triggering is one of the strategies for ovulation triggering and final maturation of oocytes. So , should be notice for luteal phase support in these cycles. At the first it was began for prevention of severe OHSS but it was associated with luteal phase problem and lower pregnancy rate due to luteolysis effects of GnRH agonists. So, two other alternative strategies have ...

Human chorionic gonadotropin (hCG) is no longer a single, omnipotent ovulation triggering option. Gonadotropin releasing hormone (GnRH) agonist, initially presented as a substitute for hCG, has led to a new era of administering GnRH agonist followed by hCG triggering. According to this new concept, GnRH agonist enables successful ovum maturation, while hCG supports the luteal phase and pregnanc...

OBJECTIVE To compare the outcomes of protocols for ovarian stimulation with recombinant hCG microdose, with GnRH agonists and antagonists for pituitary suppression. DESIGN Prospective nonrandomized clinical trial. SETTING A private assisted reproduction center. PATIENT(S) We studied 182 patients undergoing intracytoplasmic sperm injection (ICSI) cycles, allocated into two groups: GnRH ago...

Background: This study aims to verify if luteal estradiol pre-treatment improves IVF/ICSI outcomes in a GnRH antagonist protocol as compared to a micro dose GnRH agonist protocol in poor-responding patients. Materials and Methods: A total of 116 IVF/ICSI cycles were included in this prospective randomized clinical trial. The selected women were randomly assigned to receive an estradiol pre-trea...